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Background: Patients with advanced peripheral artery disease (PAD) have a high prevalence of cardiovascular (CV) risk
factors and shortened life expectancy. However, CV risk factors poorly predict midterm (<5 years) mortality in this
population. This study tested the hypothesis that baseline biochemical parameters would add clinically meaningful
predictive information in patients undergoing lower extremity bypass operations.
Methods: This was a prospective cohort study of patients with clinically advanced PAD undergoing lower extremity bypass
surgery. The Cox proportional hazard model was used to assess the main outcome of all-cause mortality. A clinical model
was constructed with known CV risk factors, and the incremental value of the addition of clinical chemistry, lipid
assessment, and a panel of 11 inflammatory parameters was investigated using the C statistic, the integrated discrimina-
tion improvement index, and Akaike information criterion.
Results: The study monitored 225 patients for a median of 893 days (interquartile range, 539-1315 days). In this study,
50 patients (22.22%) died during the follow-up period. By life-table analysis (expressed as percent surviving  standard
error), survival at 1, 2, 3, 4, and 5 years, respectively, was 90.5%  1.9%, 83.4%  2.5%, 77.5%  3.1%, 71.0%  3.8%,
and 65.3% 6.5%. Compared with survivors, decedents were older, diabetic, had extant coronary artery disease, and were
more likely to present with critical limb ischemia as their indication for bypass surgery (P< .05). After adjustment for the
above, clinical chemistry and inflammatory parameters significant (hazard ratio [95% confidence interval]) for all-cause
mortality were albumin (0.43 [0.26-0.71]; P .001), estimated glomerular filtration rate (0.98 [0.97-0.99]; P .023),
high-sensitivity C-reactive protein (hsCRP; 3.21 [1.21-8.55]; P  .019), and soluble vascular cell adhesion molecule
(1.74 [1.04-2.91]; P .034). Of the inflammatorymolecules investigated, hsCRP provedmost robust and representative
of the integrated inflammatory response. Albumin, eGFR, and hsCRP improved the C statistic and integrated
discrimination improvement index beyond that of the clinical model and produced a final C statistic of 0.82.
Conclusions: A risk prediction model including traditional risk factors and parameters of inflammation, renal function,
and nutrition had excellent discriminatory ability in predicting all-cause mortality in patients with clinically advanced
PAD undergoing bypass surgery. (J Vasc Surg 2012;56:686-95.)
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for advanced peripheral artery disease (PAD) tend to be
elderly and have a high prevalence of cardiovascular risk
factors, including diabetes mellitus, hypertension, dyslipi-
demia, and tobacco abuse. Collectively, these risk factors
are known to predict long-term mortality (10 years) but
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686re not sensitive at identifying patients at risk for death in
he near-term or midterm (5 years).1 Recently developed
isk prediction models and scoring systems of 1-year or
-year mortality in patients after lower extremity bypass
urgery have revealed that patient-specific risk factors, such
s inadequate saphenous vein, the presence of critical limb
schemia, advanced age, or the Bollinger below-knee angio-
ram score, are the most potent independent predictors.2-4
lthough these unique risk factors are unlikely to be re-
ponsible for death per se, they are most likely surrogates of
he patient’s overall frailty.
Patients with PAD are known to have increased levels of
nflammatory cytokines,5 acute-phase reactants, and solu-
le adhesion molecules, even after adjusting for age, sex,
nd traditional risk factors.6 Elderly individuals with the
ighest levels of inflammatory biomarkers have increased
hort-term mortality (5 years).7,8 Inflammation in the
AD population, as assessed by high-sensitivity C-reactive
rotein (hsCRP), not only correlates directly with severity
f PAD, which is higher in patients with critical limb
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Volume 56, Number 3 Owens et al 687ischemia (CLI), but is also associated with death and car-
diovascular events.9-11
The hypothesis of this study was that increased baseline
inflammation would add clinically meaningful value to
predicting all-cause mortality in patients undergoing lower
extremity bypass surgery. We a priori chose to examine a
panel of 11 novel and diverse inflammatory biomarkers
based on epidemiologic evidence implicating them with
adverse cardiovascular outcomes and death. We sought to
determine which biomarkers among these, if any, add
predictive value beyond that of pre-existing established risk
factors for patients undergoing lower extremity bypass
surgery.
METHODS
Study design and population. This was a National
Institutes of Health–funded prospective cohort study ex-
amining the relationship between inflammatory biomarkers
and death after lower extremity bypass surgery. Three
participating institutions underwent independent review of
the study and received approval from the respective Insti-
tutional Review Boards. Each patient provided written
informed consent. Enrollment began in February 2004 and
ended in May 2008.
Details of patient selection and inclusion and exclusion
criteria have been published previously.10,12,13 Patients
were invited to participate in this study if they planned to
undergo a lower extremity bypass operation for disabling
claudication or critical limb ischemia due to atherosclerotic
obstructive disease.
Because the hypothesis to be tested was that the base-
line inflammatory and biochemical profile was predictive of
death, we excluded anyone with active infection or concur-
rent illness that would cause a spurious increase in the
plasma concentration of inflammatory biomarkers beyond
the baseline state. Therefore, our exclusion criteria in-
cluded any evidence of active infection, pneumonia, malig-
nancy, autoimmune disorders, or other precedent or con-
current significant illness 30 days before the index bypass
procedure. Although the study accepted patients with small
ulcers or small areas of dry gangrene, patients with deep
space infections of the foot, those with large areas of
ulceration, osteomyelitis, or ulceration or gangrene requir-
ing operative debridement were excluded from participa-
tion. Also excluded were patients taking immunosuppres-
sive medications or oral steroids. Because another aim of
the present protocol involved the analysis of inflammation
on vein graft-specific outcomes, only patients undergoing a
bypass with autogenous vein were consented. The study
enrolled 225 patients.
Blood processing and assay measurements of bio-
markers. Plasma was collected with the patient in the
fasting state on the morning of the bypass procedure.
Blood was collected into ethylenediaminetetraacetic acid
and citrate Vacutainer tubes (BD Diagnostics, Franklin
Lakes, NJ) and immediately iced. Tubes were spun at 3000
rpm for 20 minutes at 4°C in a refrigerated centrifuge. All
samples were stored at 80°C until analysis. All analyses vere conducted in batch at a core laboratory to avoid
ariation.
The Modification of Diet in Renal Disease Study equa-
ion was used to estimate glomerular filtration rate (eGFR)
rom serum creatinine (SCr): eGFR (mL/min/1.73 m2)
75  (SCr)–1.15  (age)–0.203  (0.742 if female) 
1.210 if black).14 Bodymass index (BMI) was expressed as
g/m2.
Clinical and end point definitions. The end point
nvestigated in this study was all-cause mortality (death).
ace, ethnicity, and sex were assessed by self-report. Pa-
ients were considered to have hypertension if they were
aking prescription medications for hypertension or if their
ystolic blood pressure was 140 mm Hg or diastolic
lood pressure was90 mmHg. A diagnosis of hypercho-
esterolemia was present if they were taking prescription
edications for cholesterol or if they self-reported a prior
iagnosis. Patients were considered to have diabetes melli-
us if they were taking prescription medications (oral or
nsulin) for diabetes or if they self-reported a prior diagno-
is. Patients were considered to have coronary artery disease
CAD) if they had stable angina, prior myocardial infarc-
ion, a prior coronary revascularization procedure, positive
esult on a stress test, abnormal result on a coronary angio-
ram, or ischemic cardiomyopathy. Active smoking was
etermined by self-report. Former smokers were defined as
ndividuals who had smoked 100 cigarettes in their life
ut had not smoked in the past 30 days, and never-smokers
ere defined as individuals who had never smoked.
Statistical analysis. Baseline characteristics and bio-
arker values are presented as mean  standard deviation
r median (interquartile range [IQR]), depending on the
ormality of their distribution. Proportions between
roups were compared with 2 test. Correlations were
ssessed with Pearson correlation coefficients on log-
ormalized marker values. Univariate differences in plasma
evels of markers between subgroups of patients were ana-
yzed with one-way nonparametric Wilcoxon rank sum
Mann-Whitney U) tests. Standard univariate analysis was
erformed between patient demographics, laboratory and
ipid values, and inflammatory biomarkers and the primary
utcome of death by log-rank test. Inflammatory biomark-
rs were expressed as tertiles, with the lowest tertile being the
eferent. In a preliminary analysis, we explored multiple ways
o express inflammatory markers, and dividing them into
ertiles was most representative of discriminating mortality.
he exception to this was hsCRP, which we modeled as a
ichotomized variable as we have done in the past.10,12
Multivariable Cox proportional hazard modeling was
erformed on survival outcomes, and hazard ratios (HR)
nd 95% confidence intervals (CI) are presented. A test of
he proportional hazard assumption was performed for
ach covariate and globally using a formal significance test
ased on the unscaled and scaled Schoenfeld residuals. In
he model construction, we followed the natural hierarchy
f decisionmaking for the patient with PAD. First, a clinical
odel was constructed from all readily available clinical
ariables, including demographic data, medical history, and
r
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September 2012688 Owens et aldisease severity on presentation (ie, CLI or claudication).
This was noted as the clinical model, and entry into the
clinical model required a univariate value of P  .10. We
next determined the added benefit of clinical chemistry,
lipid concentrations, and inflammatory parameters condi-
tional on the clinical model.
Owing to the number of inflammatory biomarkers
examined, we broadly categorized this panel into three
groups, recognizing that there is considerable overlap
among them. The three groups included:
● The coagulation and fibrinolytic system, including
plasminogen activator inhibitor type 1, tissue plasmin-
ogen activator, and fibrinogen;
● The soluble (s) adhesion molecules and receptors,
Table I. Demographic characteristics of the study populat
Demographicsa Overall (N  225)
Age, years 67.62  10.93
Male sex 161 (71.56)
BMI, kg/m2 28.36  6.51
Hypertension 190 (84.4)
CAD 118 (52.4)
Hyperlipidemia 162 (72.0)
White race 196 (87.1)
CLI 133 (59.1)
Diabetes 117 (52.0)
Tobacco use
Former 98 (43.6)
Current 83 (36.9)
Medication use
Statin 180 (80)
Antiplatelet 182 (81)
ACEI/ARB 126 (56)
	-Blocker 183 (81.3)
ACEI, Angiotensin-converting enzyme inhibitor;ARB, angiotensin recepto
ischemia.
aContinuous variables are shown as mean  standard deviation, and catego
Table II. Clinical chemistry and lipid biomarker values
Biomarkera
Overall
(N  225)
Claudication
(n  92)
Albumin, g/dL 3.60  0.51 3.73  0.41
Hemoglobin, g/dL 11.95  1.80 12.72  1.72
WBC, 103/mm3 7.90  2.57 7,83  2.30
Calcium, mg/dL 8.64  0.54 8.65  0.51
PO4, mg/dL 3.49  1.03 3.35  0.67
eGFR, mL/min/1.73 m2 76.05  34.87 85.76  27.95
Cholesterol, mg/dL
Total 128.10  35.74 138.93  38.53 1
LDL 63.74  25.68 70.50  25.34
HDL 34.36  10.60 35.01  9.73
ApoA1, mg/dL 95.42  24.11 100.71  23.53
ApoB-100, mg/dL 57.72  17.81 63.30  17.32
Lp(a), mg/dL 33.10  32.86 33.79  33.98
Triglycerides, mg/dL 152.49  130.14 165.60  154.54 1
Apo, Apolipoprotein; CLI, critical limb ischemia; eGFR, estimated glomeru
Lp(a), lipoprotein a; PO4, phosphate; WBC, white blood cells.
aVariables are expressed as mean  standard deviation.
bP value obtained through the Student t-test or 2 test, where appropriate.including vascular cell adhesionmolecule (sVCAM-1), rintercellular adhesion molecule 1 (sICAM-1), sP-
selectin, and tumor necrosis factor (TNF) receptor
type 2 (sTNFR2), which was used as a proxy for
TNF- because it has been shown to be highly corre-
lated with TNF-, is more stable in plasma, and is
more relevant for cardiovascular-related outcomes;
and
● The inflammatory cytokines and pentraxins, including
interleukin (IL)-6, monocyte chemotactic protein-1,
hsCRP, and serum amyloid A.
Entry inclusion into the model for these parameters
equired a univariate P  .10 and a Harrell C statistic .65.
his cutoff allowed retention of a diverse set of clinical and
nflammatory parameters that we concluded adequately
e (n  175) Dead (n  50) P
7  10.75 71.66  10.69 .0029
7 (72.57) 34 (68.0) .527
7  6.18 28.70  7.64 .6804
6 (83.43) 44 (88.00) .432
5 (48.57) 33 (66.00) .030
5 (71.43) 37 (74.00) .721
9 (85.14) 47 (94.00) .099
3 (53.14) 40 (80.00) .001
5 (48.57) 32 (64.00) .054
7 (44.00) 21 (42.00) .801
5 (37.14) 18 (36.00) .883
7 (78.3) 43 (86.00) .217
2 (81.14) 40 (80.00) .545
4 (59.43) 22 (48.00) .175
1 (80.57) 42 (84.00) .993
er; BMI, body mass index; CAD, coronary artery disease; CLI, critical limb
iables as number (%).
(n  133) Pb Alive Dead Pb
 0.54 .0071 3.67  0.46 3.37  0.60 .0009
 1.65 .00001 12.12  1.78 11.36  1.75 .0077
 2.75 .7425 7.87  2.68 7.99  2.18 .7656
 0.56 .7987 8.65  0.54 8.60  0.54 .5336
 1.22 .2170 3.43  0.90 3.69  1.40 .2350
 37.61 .0004 80.80  33.17 59.52  35.89 .0001
 31.90 .0003 132.25  35.63 113.13  32.23 .0012
 25.08 .0025 66.46  26.07 54.23  22.00 .0042
 11.16 .4675 34.71  9.99 33.08  12.59 .3574
 24.16 .0289 98.92  22.78 87.80  26.86 .0050
 17.12 .0001 59.78  17.63 50.36  16.62 .0012
 32.15 .7949 35.24  33.65 25.43  28.87 .0702
 110.76 .2339 158.64  143.88 130.54  55.17 .1963
ration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein;ion
Aliv
66.4
12
28.2
14
8
12
14
9
8
7
6
13
14
10
14
r blockCLI
3.52
11.42
7.94
8.63
3.58
69.29
20.87
59.49
33.92
93.44
53.71
32.60
43.74
lar filtepresented the patient’s biochemistry.
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Volume 56, Number 3 Owens et al 689The ability to classify risk was assessed by the use of the
Harrell C statistic.15 To determine the degree of risk reclas-
sification, the integrated discrimination improvement in-
dex (IDI) was used. The IDI can be thought of as indicat-
ing how far individuals are moving on average along the
continuum of predicted risk; that is, how well a model
separates individuals by the outcome of interest (death) by
estimating the change in the difference in the mean pre-
dicted probabilities of the outcome between those with and
without the outcome in question after introducing the
candidate biomarker to the model.16 Finally, we sought to
obtain the most parsimonious model by minimizing the
Akaike information criterion (AIC), which is a metric of the
goodness-of-fit and accounts for the number of parameters
required to obtain that degree of fitness. Statistical analyses
were performed on Stata/SE 11.0 software (StataCorp LP,
College Station, Tex).
RESULTS
Population demographics. The demographic sum-
mary of the study population is presented in Table I. The
indication for bypass surgery was CLI in 133 patients
(59.1%), classified as Fontaine 2b in 92, Fontaine 3 in 60,
and Fontaine 4 in 73. The mean follow-up from the index
bypass procedure was 925 days (median, 893; IQR, 539-
1315 days). No surviving individual was monitored 365
days. Fifty patients (22.2%) died during the follow-up
period. By life-table analysis (expressed as percentage sur-
viving  standard error), survival at 1, 2, 3, 4, and 5 years,
respectively, was 90.5%  1.9%, 83.4%  2.5%, 77.5% 
3.1%, 71.0%  3.8%, and 65.3%  6.5%. Two deaths
occurred30 days and 28 deaths1 year. Compared with
survivors, decedents were older (mean age, 71.7  10.7 vs
66.5  10.8 years; P  .003), had a higher incidence of
established CAD (66% vs 49%; P  .030), and were more
likely to present with CLI as their indication for bypass
surgery (80% vs 53.1%; P  .001; Table I). The use of a
statin at the time of bypass was not associated with survival;
however, only 45 patients (20%) were not taking a statin
and only seven deaths occurred among these individuals
during follow-up.
The bypass graft characteristics and outcomes have
been published elsewhere.10,12,13 In brief, 202 bypass
grafts were constructed from a single segment or composite
great saphenous vein and 23 were from an arm vein. There
were 111 femoral-popliteal, 78 femoral-tibial, and 36 femoral
or popliteal-pedal bypass grafts. The 2-year primary and sec-
ondary patency rates were 61.4% 3.6% and 83.1% 2.7%,
respectively.
Concentrations of albumin, hemoglobin, and eGFR
were all significantly lower in the CLI subgroup (Table II).
As expected, most biomarkers of inflammation were higher
in patients who presented with CLI compared with those
presenting with claudication (Table III). However, there
was no difference in the white blood cell count (Table II).
The finding of no difference in white blood cell count
between CLI and claudication patients was expected given
our stringent exclusion criteria for entry into this study. eotal cholesterol, low-density lipoprotein (LDL) choles-
erol, and apolipoprotein (apo) A1 and apoB100 were
ower in patients presenting with CLI (Table II).
Biomarkers and death. Baseline albumin, hemoglo-
in, eGFR, and total cholesterol and LDL cholesterol
oncentrations were lower in decedents than in survivors
log-rank P .05; Table II). In particular, albumin (3.37
.60 vs 3.67 0.46 mg/dL; P .0009) and eGFR (59.5
5.9 vs 80.8  33.2 mL/min/1.73 m2; P  .0001) were
ignificantly lower in patients who subsequently died com-
ared with those who survived. By contrast, baseline levels
f all inflammatory cytokines and pentraxins, fibrinogen,
nd all soluble receptors and cell adhesion molecules, ex-
ept sP-selectin, were markedly elevated in patients who
ubsequently died (Table III). All biomarkers were posi-
ively and significantly correlated with one another and
egatively correlated with albumin (P .0002 for all correla-
ions). The Pearson correlation coefficient between albumin
nd total cholesterol was .27 (P  .0006), reflecting the
utritionally depleted state in patients who subsequently died
uring follow-up.However, therewas no correlation between
lbumin and the patient’s BMI (P .07).
Table IV summarizes the univariate association ex-
ressed as HR (95% CI) and as the C statistic between
atient demographics and laboratory and lipid values with
ll-cause mortality. All biomarkers were modeled as tertiles
ith the exception of CRP. The biomarker CRP was mod-
led as a dichotomized variable with a cutoff of 5 mg/L.
e chose to do this because our previous work has shown
hat CRP offers the best ability to discriminate between
atients undergoing lower extremity bypass surgery into
hose with and without adverse graft-related events.10 Fur-
her, patients with CRP levels 5 mg/L exhibit impaired
ein graft remodeling compared with patients with lower
RP levels, implying that this value is clinically relevant in
ein graft-related outcomes.12 In addition, hsCRP 5
g/L had a sensitivity of 70.2% and specificity of 72.0% for
ubsequent midterm mortality. This represents the highest
um of sensitivity and specificity and therefore is an optimal
utoff for this analyte. By univariate analysis, an hsCRP
evel 5 mg/L was associated with increased mortality
HR, 4.54; 95% CI, 2.43-8.49; P  .0001; Fig 1).
In multivariable analysis, clinical risk factors that met
he inclusion criteria included age, diabetes mellitus, the
resence of established CAD, and CLI as an indication for
ypass. Clinical and inflammatory biomarker values that
et the inclusion criteria included albumin, eGFR, hsCRP,
VCAM-1, sTNFR2, and fibrinogen (Table V). Represen-
ative biomarkers from each of the three broad categories
ere present in the final model. Although IL-6 formally
et the inclusion criteria into the final model, it was
mitted given its known role of induction of CRP produc-
ion.17 Lower tertiles of total cholesterol, LDL, high-
ensity lipoprotein, and apoA1 and apoB100 were associ-
ted with decreased survival on univariate analysis;
owever, no lipid parameter met the inclusion criteria for
he final model. The HRs and 95% CI of all variables
ntered into the final model are presented in Table V.
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September 2012690 Owens et alHigher eGFR (HR, 0.98; 95% CI, 0.97-0.99; P  .023)
and albumin (HR, 0.43; 95% CI, 0.26-0.71; P  .001)
were protective for overall death, whereas higher hsCRP
5 mg/L (HR, 3.21; 95% CI, 1.21-8.55; P  .019) and
sVCAM-1 (HR, 1.74; 95% CI, 1.04-2.91; P  .034) were
predictive of death. The hazard of reduced serum albumin
was linear through the full range of albumin (2.2 to 4.9
mg/dL). In addition, albumin predicted death equally well
for patients with high levels of inflammatory biomarkers,
assessed as hsCRP 5 mg/L (HR, 0.48; 95% CI, 0.28-
0.83), as it did for patients with hsCRP 5 mg/L (HR,
0.49; 95% CI, 0.29-0.84), indicating an effect size that was
independent of the patient’s inflammatory state. Although
the HR for each unit increase of eGFR was marginal at
0.98, the hazard for reduced renal function begins well
before the onset of hemodialysis.18 In the present analysis,
each standard deviation 35 mL/min/1.73 m2–increase in
eGFR had an HR of 0.54.
The clinical model produced a C statistic of 0.71 (Table
VI). When eGFR, albumin, and hsCRP were added to the
model, the C statistic was increased to 0.82. Among all of
the biochemical parameters investigated, albumin contrib-
Table III. Inflammatory marker values broadly grouped in
molecules and receptors, and inflammatory cytokines and p
Biomarkera
Overall
(N  225)
Claudication
(n  92)
Coagulation and
fibrinolytic factors
PAI-1, ng/mL 52.78 50.33
(31.84-87.83) (28.07-88.84)
tPA, ng/mL 9.95 10.03
(5.39-14.03) (5.39-13.25)
Fibrinogen, mg/dL 479.95 438.60
(401.00-585.00) (381.30-504.50
Soluble cell adhesion
molecules and receptors
P-selectin, ng/mL 51.12 49.04
(38.05-69.38) (37.34-68.79)
VCAM-1, ng/mL 706.40 604.90
(536.75-1079.55) (462.80-836.40
ICAM, ng/mL 261.35 247.50
(218.65-322.55) (212.40-315.10
sTNFR2, ng/mL 2.80 2.28
(2.12-4.32) (1.89-3.09)
Inflammatory cytokines
and pentraxins
IL-6, pg/mL 4.74 2.78
(2.01-10.22) (1.50-5.22)
CRP, mg/L 2.98 1.81
(1.28-12.25) (0.92-3.95)
SAA, mg/dL 0.86 0.62
(0.42-2.09) (0.32-0.93)
MCP-1, pg/mL 215.65 196.10
(176.90-278.50) (168.30-248.90
CLI, Critical limb ischemia; CRP, C-reactive protein; ICAM, intercellular a
PAI-1 plasminogen activator inhibitor type 1; SAA, serum amyloid A; sTNF
VCAM-1, vascular cell adhesion molecule.
aValues are presented as median (interquartile range).
bKruskal-Wallis rank test.uted the largest increase in the C statistic (0.09) beyond the tlinical model. The addition of hsCRP to the clinical model
lus eGFR and albumin improved the C statistic by 0.02.
he IDI, an assessment of incremental improvement in risk
iscrimination after addition of a new predictor, was esti-
ated for the addition of eGFR, albumin, and hsCRP to
he clinical model, and all were highly significant (Table
I). The addition of other clinical or inflammatory markers
sVCAM, sTNFR2) failed to significantly improve the dis-
riminatory ability of the final model, which consisted of
ge, diabetes, CAD, CLI, albumin, eGFR, and hsCRP.
ISCUSSION
Management decisions for patients with severe PAD
re based on multiple levels of information processed in
natural hierarchical order; for example, demographic
haracteristics, prevalent and medical history, and clini-
al presentation are considered first, followed by results
f routine laboratory and angiographic tests. The addi-
ion of a biomarker must be predicated on its ability to
rovide clinically meaningful information above that
rovided by routine history, examination, and laboratory
oagulation and fibrinolytic factors, soluble cell adhesion
axins
I (n  133) Pb Alive Dead Pb
53.46 .6561 51.89 57.96 .1990
.89-86.38) (30.44-85.46) (34.01-111.16)
9.70 .8292 9.77 10.25 .4936
3-15.19) (5.36-13.96) (5.89-15.44)
521.30 .0001 463.05 587.35 .0001
7.20-624.30) (390.85-545.30) (473.80-673.80)
51.89 .5173 51.51 50.74 .6949
.39-70.67) (38.18-70.41) (37.93-66.38)
801.3 .0001 655.90 1048.70 .0001
6.8-1310.45) (505.90-944.60) (682-80-1496.0)
267.85 .0956 251.60 288.00 .0071
0.95-338.75) (215.50-315.20) (244.20-360.80)
3.41 .0001 2.65 3.81 .0001
8-5.34) (2.02-3.81) (2.78-8.07)
6.67 .0001 3.63 10.97 .0001
5-12.83) (1.58-8.12) (4.70-23.68)
5.53 .0001 2.39 13.97 .0001
8-21.68) (1.20-5.58) (2.94-41.19)
1.33 .0001 0.77 2.14 .0001
6-4.5) (0.41-1.48) (0.64-9.26)
229.70 .0014 208.50 253.60 .0100
0.80-308.40) (174.00-265.00) (181.10-357.40)
n molecule; IL-6, interleukin 6; MCP-1, monocyte chemotactant protein;
oluble tumor necrosis factor receptor 2; tPA, tissue plasminogen activator;to c
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Volume 56, Number 3 Owens et al 691For any risk model to have practical value, it must be
intuitive and easy to incorporate into clinical practice. The
final model constructed in this study contains a diverse set
of variables, including traditional demographics, such as
age and diabetes, severity of PAD, a measure of renal
function, an assessment of protein-energy malnutrition, and a
marker of inflammation. The seven parameters represented in
the final model are naturally intuitive and readily obtained in a
physician’s office; hence, its practical value. In addition, the
final model has a C statistic of 0.82, which is within the range
considered to have excellent discriminatory ability.19 A C
statistic of 0.82 indicates that the model can adequately dis-
criminate between a randomly selected patient who dies dur-
ing follow-up and a randomly selected patient who survives,
82% of the time. Finally, the model minimizes the AIC, a
Table IV. Univariate association of demographic, clinical,
Predictor variables HR (
Baseline demographics and disease presentation
Age 1.
Male sex 0.
White race 0.
Diabetes mellitus 1.
CAD 1.
Hypertension 1.
Hyperlipidemia 1.
Tobacco (current) 0.
CLI 3.
Clinical laboratory values
Albumina 0.
Hemoglobina 0.
WBCa 1.
Calcium 0.
Phosphate 1.
eGFR 0.
Lipid values
Total cholesterola 0.
LDLa 0.
HDLa 0.
Apolipoprotein A1a 0.
Apolipoprotein B100a 0.
Lp(a)a 0.
Triglyceridesa 1.
Fibrinolytic factors
PAI-1 1.
tPA 1.
Fibrinogen 2.
Soluble cell adhesion molecules and receptors
sP-selectin 0.
sVCAM-1 2.
sICAM-1 1.
sTNFR2 1.
Inflammatory cytokines and pentraxins
Interleukin-6 2.
hsCRP 5 mg/L 4.
MCP-1 1.
SAA 1.
CAD, Coronary artery disease; CI, confidence interval; CLI, critical limb isch
HR, hazard ratio; hsCRP, high-sensitivity C-reactive protein; LDL, low-den
PAI-1 plasminogen activator inhibitor type 1; SAA, serum amyloid A; sIC
necrosis factor receptor 2; sVCAM-1, soluble vascular cell adhesion molecu
aBiomarker was modeled as a tertile.metric of goodness-of-fit and complexity, because it imposes a denalty for the number of parameters needed to achieve the
articular degree of fitness. It is a quantification of model
reference seeking the fewest explanatory variables required to
rovide adequate fit to the data.
One of the immediate observations of the multivariable
odel is that traditional risk factors, including cholesterol
ractions and smoking, were not significantly associated
ith the primary end point of midterm death in this cohort.
ather, impaired renal function, malnutrition, and inflam-
ation were the most powerful predictors. This is consis-
ent with previous investigations that have shown markers
f inflammation are better predictors of short-term and
idterm mortality, whereas traditional cardiovascular risk
actors are better in the long-term (10 years).7,11,20,21
odels incorporating more proximate causes of midterm
lipid parameters with all-cause mortality
I) for death P C statistic
.01-1.07) .003 0.6288
.46-1.54) .598 0.5146
.29-1.32) .224 0.5335
.95-3.01) .074 0.5618
.09-3.53) .023 0.6002
.61-3.38) .401 0.5152
.57-2.04) .791 0.5114
.43-1.37) .379 0.5352
.67-6.71) .001 0.6358
.24-0.58) .0001 0.7049
.37-0.78) .001 0.6213
.79-1.62) .479 0.5397
.43-1.23) .242 0.5655
.75-1.45) .789 0.4297
.97-0.99) .0001 0.6503
.43-0.91) .014 0.6218
.40-0.86) .007 0.6415
.43-0.92) .018 0.6178
.45-0.96) .034 0.5984
.43-0.90) .013 0.6158
.59-1.19) .351 0.5386
.75-1.50) .727 0.4982
.83-1.70) .332 0.5395
.73-1.49) .792 0.5305
.50-3.33) .0001 0.6810
.65-1.32) .705 0.5061
.45-3.20) .0001 0.6824
.16-2.42) .006 0.6452
.32-2.83) .001 0.6572
.58-3.56) .0001 0.6943
.43-8.49) .0001 0.7001
.00-2.06) .049 0.5759
.29-2.81) .001 0.6453
eGFR, estimated glomerular filtration rate;HDL, high-density lipoprotein;
oprotein; Lp(a), lipoprotein (a);MCP-1, monocyte chemotactant protein;
, soluble ICAM, intercellular adhesion molecule; sTNFR2, soluble tumor
, tissue plasminogen activator; WBC, white blood cell.and
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September 2012692 Owens et alsions but to allow for a potentially mitigating intervention.
Identification of a high-risk patient may encourage the
practitioner to choose a less invasive alternative to bypass
such as endovascular revascularization. Understanding
midterm survival seems especially prudent in light of the
recently completed Bypass versus Angioplasty for Severe
Ischaemia of the Leg (BASIL) trial demonstrating an over-
all survival advantage in patients randomized to bypass
surgery in patients who survived at least 2 years.2
We felt it was unlikely that onemarker could adequately
represent the total inflammatory burden and that the simul-
taneous measurement of a panel of biomarkers would more
adequately represent the integrated inflammatory risk.
Thus, we measured 11 novel markers from three broad
Fig 1. Nelson-Aalen cumulative hazard estimates for death are
shown for patients dichotomized by preoperative baseline high-
sensitivity C-reactive protein (hsCRP) values higher or lower than
5.0 mg/L.
Table V. Clinical and inflammatory biomarker values
that met the inclusion criteria
Variable
Parameter
estimatea HR (95% CI) P
Age –0.003  0.017 0.99 (0.96-1.03) .859
Diabetes 0.125  0.410 1.10 (0.50-2.41) .807
CAD 0.490  0.412 1.59 (0.72-3.52) .249
CLI 0.614  0.475 1.86 (0.73-4.73) .192
eGFR 0.013  0.006 0.98 (0.97-0.99) .023
hsCRP 
5 mg/L 1.15  0.499 3.21 (1.21-8.55) .019
Albumin
(tertiles) 0.835  0.254 0.43 (0.26-0.71) .001
sVCAM-1
(tertiles) 0.595  0.300 1.74 (1.04-2.91) .034
sTNFR2
(tertiles) 0.101  0.341 0.90 (0.46-1.76) .767
Fibrinogen
(tertiles) 0.277  0.327 0.75 (0.39-1.43) .391
CAD, Coronary artery disease; CI, confidence interval; CLI, critical limb
ischemia; eGFR, estimated glomerular filtration rate; HR, hazard ratio;
hsCRP, high-sensitivity C-reactive protein; sTNFR2, soluble tumor necrosis
factor receptor 2; sVCAM-1, soluble vascular cell adhesion molecule.
aPresented with the standard error.categories: thrombotic/fibrinolytic, soluble cell surface re- neptors and adhesion molecules, and inflammatory cyto-
ines and acute-phase reactants. However, the addition of
sCRP to the full clinical model plus eGFR and albumin
ssentially quenched the model from further contribution
f any other inflammatory biomarker. Although sVCAM
etained statistical significance in the multivariable model,
o additional clinically meaningful information, as deter-
ined by the C statistic or the IDI, was gained from its
nclusion. In this regard, hsCRP has proved the most
obust marker for inflammation in this cohort of patients
ndergoing lower extremity bypass surgery.
The inclusion of the full biomarker panel, however, is
euristic because enrolled patients, particularly those who
ied during follow-up, had a marked elevation in proin-
ammatory cytokines such as sTNFR2 and IL-6. These
ytokines elicit an acute-phase response that has profound
utritional implications.22 It is energy-intensive, with high
ates of hepatic protein synthesis, and requires large quan-
ities of essential amino acids. Through a variety of de-
cribed pathways,23 long-term exposure to elevated levels
f cytokines enhances protein catabolism and induces an-
rexia, and lean muscle mass is expended to support syn-
hesis of acute-phase proteins. The culmination of these
rocesses creates a state of vascular cachexia. Indeed, the
alues of IL-6 and sTNFR2 in patients who died during
ollow-up were comparable to those in patients with
dvanced-stage congestive heart failure and those with
nown cardiac cachexia.24,25 Similar to other forms of
able VI. Model diagnostics: Cox proportional hazard
odel C statistic for all-cause midterm mortality, Akaike
nformation criterion (AIC), and integrated improvement
ndex (IDI)a
isk markers C statistic AIC
linical model rf 0.7072 485.01
linical model rf 
 eGFR 0.7179 481.73
linical model rf 
 eGFR 
 albumin 0.7986 352.35
linical model rf 
 eGFR 
 albumin 

hsCRP 5 mg/L 0.8200 325.00
linical model rf 
 eGFR 
 albumin 

hsCRP  5 mg/L 
 sVCAM-1 0.8190 320.78
DI Estimate P
DI adding eGFR to clinical model rf 0.03358 .03284
DI adding albumin to clinical model
rf 
 eGFR 0.06786 .00048
DI adding hsCRP to clinical model
rf 
 eGFR 
 albumin 0.08352 .00005
DI adding sVCAM to clinical model
rf 
 eGFR 
 albumin 
 hsCRP
5 mg/L 0.01200 .17352b
GFR, Estimated glomerular filtration rate; hsCRP, high-sensitivity C-reac-
ive protein; rf, risk factor; sTNFR2, soluble tumor necrosis factor receptor
; sVCAM-1, soluble vascular cell adhesion molecule.
Clinical model rf includes age, diabetes mellitus, coronary artery disease,
ritical limb ischemia.
P for the addition of sVCAM-1, sTNFR2, and fibrinogen is not significant.onmalignant cachexia, this is a chronic hypercytokinemic
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Volume 56, Number 3 Owens et al 693cachexia, with relative preservation of body weight and
BMI in most patients.26 For example, only 32 patients in
this study had a BMI 22 kg/m2, and no correlation
existed between BMI and albumin. Along with albumin,
reduced hepatic production of lipoproteins is also asso-
ciated with the inflammatory/malnourished state.27
Cholesterol fractions and both apoA1 and apoB100 were
decreased in patients who died in this study. However,
the seemingly paradoxic finding that lower total choles-
terol, high-density lipoprotein, LDL, apoA1, and
apoB100 had significant univariate association with
death was mitigated by inclusion of inflammatory, nutri-
tional, and renal parameters. Therefore, in this study as
in others, the so-called J-shaped association between
lipid parameters and death is probably a result of con-
founding.28
The combined effect of inflammation, renal failure, and
malnutrition has received little attention in patients under-
going lower extremity bypass despite the considerable over-
lap among them. Synergism of each to the hazard of death
can be demonstrated by Venn diagrams, with relative mal-
nourishment (albumin 3.5 mg/dL; n  74), renal im-
pairment (eGFR60 mL/min; n 63), and high levels of
inflammation (hsCRP5 mg/L; n 80) represented (Fig
2). This is particularly alarming, because the 21 patients
(9%) located at the convergence of all three circles had an
HR of death of 9.08 (95% CI, 4.85-17.01); therefore, even
modest impairment of more than one of these three do-
Inflammation (hsC
Malnutrition (albumin < 3.5mg/dl)
18
57
9
21
15
HR=6.7
HR=4.5
HR=3.77
HR=9.0
56.5=RH
Fig 2. A Venn diagram demonstrates the overlap among
inflammation and shows the synergism of different mech
this study, 74 (33%) had an estimated glomerular filtra
albumin concentration of 3.5 mg/dL, and 80 (36%) h
of 5.0 mg/L. The 21 patients (9%) located within themains has a substantial clinical consequence. mLimitations. Among the study imitations are that the
ohort consisted predominantly of elderly white men. Fur-
her studies are needed to determine whether this model
mproves risk stratification in women, younger individuals,
nd other ethnic groups.
Some biomarker values in this study were extremely
levated. Because of the strict exclusion criteria applied and
o the best of our knowledge, the elevated marker values
ikely reflect the true baseline state of the patient rather than
purious elevation due to concurrent illness. Albumin,
hich has a half-life of approximately 20 days, was used as a
utritional index in this examination. It is possible that
nother metric of nutrition would have been more appro-
riate, such as transthyretin (prealbumin; half-life of 2
ays), which is more sensitive than albumin to changes in
rotein-energy status.29 However, although transthyretin
ccurately reflects recent nitrogen intake, albumin may
etter represent the overall baseline nutritional state of the
atient.30 Finally, this study was modest in size and results
ust be considered with caution until external validation
tudies can be undertaken.
Study implications. Several methods, including the C
tatistic, IDI, and AIC, were used to provide diagnostic
nformation about model iterations. Together these mea-
ures not only quantify calibration and discrimination but
lso ensure that the most parsimonious model is used to
est fit the data. A model incorporating biochemical pa-
ameters has theoretic advantages to guide potential treat-
 5mg/L)
al impairment (eGFR <60 ml/min)
23
21
HR=2.72
01.4=RH
ets of patients with malnutrition, renal impairment, and
s for the hazard ratio (HR) of death. Of 225 patients in
ate (eGFR) 60 mL/min/1.73 m2, 63 (28%) had an
h-sensitivity C-reactive protein (hsCRP) concentration
ection of all three circles have an HR for death of 9.08.RP>
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September 2012694 Owens et aljects. Anti-inflammatory or anticytokine therapy may
mitigate some of the effects of the acute-phase response
seen in this population.31,32 Nutritional therapy with -3
fatty acids, appetite stimulants, or metabolic regulators
have shown promise in similar cohorts andmay improve the
recovery period after surgery and improve functional capac-
ity.33,34 Progressive resistive training has been shown to
improve lean mass and biochemical parameters in patients
with high levels of inflammation. Whether any of these
therapies could improve outcomes in the clinically ad-
vanced PAD population is currently unknown.
CONCLUSIONS
The risk model we have presented containing parame-
ters of inflammation, nutrition, and renal function has
excellent discriminatory ability for midterm all-cause mor-
tality in patients selected to undergo lower extremity arte-
rial bypass surgery. Among all markers of inflammation,
hsCRP has proven the most robust and is most representa-
tive of the integrated inflammatory response. A significant
minority of patients undergoing lower extremity bypass
surgery present with a hypercytokinemic, hypoalbumin-
emic vascular cachexia that places them at a particularly
increased risk for death. Whether there are any therapeutic
mitigating strategies to decrease the inflammatory response
or improve the biochemical parameters in these high-risk
patients remains to be tested.
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